Literature DB >> 7844562

Protection of hamsters against experimental mumps virus (MuV) infection by antibodies raised against the MuV surface glycoproteins expressed from recombinant vaccinia virus vectors.

S Houard1, T M Varsanyi, F Milican, E Norrby, A Bollen.   

Abstract

The fusion (F) and haemagglutinin-neuraminidase (HN) glycoproteins of mumps virus (MuV) have been produced in CV1 cells via vaccinia virus recombinants. Recombinant proteins accumulated in infected cells and were glycosylated. Upon reduction, the F protein product was completely converted into its subunits. Hamsters infected with vaccinia recombinants expressing either the F or HN proteins produced antibodies recognizing MuV antigens and neutralizing MuV infectivity in vitro. These antibodies provided protection against MuV-induced encephalitis in newborn hamsters.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844562     DOI: 10.1099/0022-1317-76-2-421

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.

Authors:  Steven A Rubin; Malen A Link; Christian J Sauder; Cheryl Zhang; Laurie Ngo; Bert K Rima; W Paul Duprex
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity.

Authors:  B Halassy; T Kurtović; M Brgles; M Lang Balija; D Forčić
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  In vitro and in vivo growth alter the population dynamic and properties of a Jeryl Lynn mumps vaccine.

Authors:  Sarah M Connaughton; Jun X Wheeler; Eva Vitková; Philip Minor; Silke Schepelmann
Journal:  Vaccine       Date:  2015-07-15       Impact factor: 3.641

4.  Importance of reporting sequence & serological data from mumps outbreaks in unvaccinated populations.

Authors:  Sarah Connaughton
Journal:  Indian J Med Res       Date:  2016-01       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.